GlassScriptPhysician profile
Manjusha Anna
NPI 1972890994
$2,634.90
in general payments reported to CMS, 2019-2025
26 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.07 · 2021: $470 · 2022: $468 · 2023: $594 · 2024: $490 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $640.18 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $420.62 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $280.40 | 2021-2025 | Watchman Flx, Watchman Access System |
| Abiomed | $230.89 | 2021 | |
| Janssen Pharmaceuticals, INC | $175.61 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $143.89 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $127.32 | 2022-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.30 | 2022-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.07 | 2019 | |
| Irhythm Technologies, INC. | $68.44 | 2021-2022 | |
| Pfizer INC. | $65.54 | 2022-2023 | |
| Novo Nordisk INC | $46.78 | 2023 | Ozempic |
| Impulse Dynamics (USA) INC. | $33.70 | 2025 | Optimizer |
| Preventice Services, LLC | $31.31 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $29.30 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.31 | 2024 | |
| Siemens Medical Solutions USA, INC. | $23.70 | 2022 | |
| Scpharmaceuticals INC. | $22.42 | 2024 | |
| Lilly USA, LLC | $21.03 | 2025 | Zepbound, Mounjaro |
| Alnylam Pharmaceuticals INC. | $18.79 | 2022 | |
| Glaxosmithkline, LLC. | $17.61 | 2025 | Shingrix, Arexvy |
| Abbott Laboratories | $15.00 | 2019 | |
| Itamar Medical INC | $14.68 | 2021 | |
| Esperion Therapeutics, INC. | $14.65 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.92 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjusha Anna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.